Comparison of tiotropium bromide and combined ipratropium/salbutamol for the treatment of COPD: A UK General Practice Research Database 12-month follow-up study

Primary Care Respiratory Journal

Volumn 17, Issue 2, 2008, Pages 104-110

  Griffin, Jane ^a   Lee, Sally ^a   Caiado, Maria ^a   Kesten, Steven ^b   Price, David ^c  

^a BOEHRINGER INGELHEIM LTD   (United Kingdom)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

COPD; General practice database; Hospitalisation; Ipratropium salbutamol; Tiotropium

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; SALBUTAMOL; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DATA BASE; DISEASE EXACERBATION; DRUG EFFICACY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; GENERAL PRACTICE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PATIENT REFERRAL; PROGNOSIS; RISK REDUCTION; TREATMENT OUTCOME; UNITED KINGDOM;

AGED; ALBUTEROL; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; FAMILY PRACTICE; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HOSPITALIZATION; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REFERRAL AND CONSULTATION; RETROSPECTIVE STUDIES; SCOPOLAMINE DERIVATIVES; TREATMENT OUTCOME;

EID: 45349103384     PISSN: 14714418     EISSN: 14751534     Source Type: Journal    
DOI: 10.3132/pcrj.2008.00024     Document Type: Article

References (23)

1. Pauwels RA, Buist S, Calverley PMA, et al. Global initiative for chronic obstructive Lung Disease. Bethesda: National Heart, Lung & Blood Institute/World Health Organisation, 2003.
2. Dewan NA, Fafique S, Kanwar B, et al. Acute exacerbation of COPD, factors associated with poor treatment outcome. Chest 2000;117:662-71.
3. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000;117:398S-401S.
4. Andersson F, Borg S, Jansson SA, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:7000-08.
5. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52.
6. Miravitlles M, Murio C, Guerrero R, et al. Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest 2003;123:784- 91.
7. Oostenbrink JB, Rutten-van Mölken MPMH. Resource use and risk factors in high cost exacerbations of COPD. Respir Med 2004;98:883-91.
8. Pearson M. Chronic obstructive pulmonary disease: Nation clinical guideline on management of Chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59 (Suppl 1):1-232.
9. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 year's treatment with tiotropium. Eur Respir J 2002;19:209-16.
10. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-24.
11. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003;58:399- 404.
12. O'Donnell DE Flüge T, Gerken F, et al. Effect of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-40.
13. Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator. Ann Intern Med 2005;143:317-26.
14. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with once-daily tiotropium in patients with COPD. Chest 2005;128:1168-78.
15. Barr RG, Bourbeau J, Camargo CA, Ram RFS. Tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Review 2005. Issue 2. Art. No.: CD002876.
16. GPRD. Available at: www.gprd.com/home/ [Accessed: 26 October 2007]. 17. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41- 55.
17. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127:757-63.
18. Gu XS, Rosebaum PR. Comparison of multivariate matching methods: structures, distances, and algorithms. J Comput Graph Stat 1993;2:405-20.
19. Drake C. Effect of misspecification of the propensity score on estimators of treatment effect. Biometrics 1993;49:1231-6.
20. Pearson M, Ayres JG, Sarno M, Massey D, Price D. Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management Reassessment) programme 1997-2001. Int J Chron Obstruct Pulmon Dis 2006;1(4):435-43.
21. Freeman D, Lee A, Price D, et al. Efficacy and safety of tiotropium in COPD patients in primary care - the SPiRiva Usual CareE (SPRUCE) study. Respir Res 2007;8:45.
22. Soriano JB, Maier WC, Visick G, Pride NB. Validation of general practictioner-diagnosed COPD in the UK General Practice Research Database. Eur J Epidemiol 2001;17(12):1075-80.
23. Jara M, Lanes SF, Wentworth C 3rd, May C, Kesten S. Comparative safety of long-acting inhaled bronchodilators: a cohort study using the UK THIN primary care database. Drug Saf 2007;30(12):1151-60.